SWITCHING FROM ADALIMUMAB TO SARILUMAB IS ASSOCIATED WITH COMPARABLE EFFICACY BUT LOWER FUNCTIONAL IMPROVEMENT VERSUS CONTINUOUS SARILUMAB MONOTHERAPY THROUGH 48-WEEK OPEN-LABEL EXTENSION (OLE) OF THE PHASE 3 MONARCH TRIAL

Category Primary study
JournalANNALS OF THE RHEUMATIC DISEASES
Year 2018
This article has no abstract
Epistemonikos ID: 0be9ae0dbfbb86a96e06daa9bfc16330f1bde8ed
First added on: Feb 09, 2025